Look up one drug

Apo-Glyburide · DIN 01913654 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1991-12-31 · brand APO GLYBURIDE TAB 2.5MG · ATC A10BB01 GLIBENCLAMIDE · form Tablet · route Oral · ingredients GLYBURIDE 2.5 MG · company Apotex inc · schedule Prescription

DIN 01913654: Apo-Glyburide Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002009; group id 747; item number 1829; lccId None; manufacturer id APX Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0321; ministry $0.0321 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01913654 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11728

Interchangeable products

Diabeta · DIN 02224550 · not recorded Sandoz Glyburide · DIN 02248008 · $0.0321 Teva-Glyburide · DIN 01913670 · $0.0321

Shortage status: resolved shortage (ended 2020-10-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01913654

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Glyburide · DIN 01913670 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2010-10-09 · brand TEVA-GLYBURIDE · ATC A10BB01 GLIBENCLAMIDE · form Tablet · route Oral · ingredients GLYBURIDE 2.5 MG · company Teva canada limited · schedule Prescription

DIN 01913670: Teva-Glyburide Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002009; group id 747; item number 1829; lccId None; manufacturer id TEV Source form: Tab; strength: 2.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0321; ministry $0.0321 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01913670 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11780

Interchangeable products

Apo-Glyburide · DIN 01913654 · $0.0321 Diabeta · DIN 02224550 · not recorded Sandoz Glyburide · DIN 02248008 · $0.0321

Shortage status: discontinued (2015-09-02, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01913670

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Apo-Glyburide · DIN 01913662 Manufacturer: Apotex Inc.; listing date 1996-10-01 Health Canada: Marketed since 1991-12-31 · brand APO GLYBURIDE TAB 5MG · ATC A10BB01 GLIBENCLAMIDE · form Tablet · route Oral · ingredients GLYBURIDE 5 MG · company Apotex inc · schedule Prescription

DIN 01913662: Apo-Glyburide Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002004; group id 747; item number 1830; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0574; ministry $0.0573 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01913662 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11727

Interchangeable products

Diabeta · DIN 02224569 · not recorded Glyburide · DIN 02350467 · $0.0573 Teva-Glyburide · DIN 01913689 · $0.0573

Shortage status: discontinued (2018-12-11, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01913662

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

Teva-Glyburide · DIN 01913689 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2010-10-09 · brand TEVA-GLYBURIDE · ATC A10BB01 GLIBENCLAMIDE · form Tablet · route Oral · ingredients GLYBURIDE 5 MG · company Teva canada limited · schedule Prescription

DIN 01913689: Teva-Glyburide Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002004; group id 747; item number 1830; lccId None; manufacturer id TEV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0574; ministry $0.0573 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01913689 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11781

Interchangeable products

Apo-Glyburide · DIN 01913662 · $0.0573 Diabeta · DIN 02224569 · not recorded Glyburide · DIN 02350467 · $0.0573

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01913689

Shortage record checked 2026-09-13T08:10:21.292534+00:00